Details: pack, label wording, sources, registration
Ono 8 mg/4 ml, Solution
4 ml ampoule, solution for injection, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
Off-label IV or IM ondansetron for short-term control of clinically important nausea and active vomiting in dogs
6.9/10
Situational / acceptable
Details →
8 mg/4 ml, 4 ml ampoule, solution for injection, human medicine
Assessed clinical scope Dog · Off-label IV or IM ondansetron for short-term control of clinically important nausea and active vomiting in dogs · IV,IM
Care setting Clinic or hospital treatment after assessment of the cause, hydration, electrolytes and obstruction risk; repeated dosing and response are supervised by the veterinary team
vetman score
6.9/10
Situational / acceptable
Evidence confidence: Medium
Georgia: Yes, human · № რ-041727 · Verified on 16 Oct 2026
Off-label use
A useful off-label hospital antiemetic with direct canine IV efficacy evidence and accurate 2 mg/ml dosing. Select the patient and cause carefully, give IV doses slowly, and monitor higher-risk cardiac, electrolyte, hepatic or serotonergic-drug cases; IM use is less directly studied.
Regulatory and scientific credibility 6.0/10
The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and its animal use remains off-label.
Clinical efficacy 7.5/10
A blinded placebo-controlled crossover trial showed rapid benefit from IV ondansetron for vestibular nausea, and prospective parvoviral studies support antiemetic activity in hospitalised dogs. Evidence is strongest for IV use; IM use and broad extrapolation across every cause of vomiting are less directly studied.
Safety and tolerability 6.5/10
Ondansetron is generally well tolerated at veterinary doses, but these exact human products have no dog- or cat-specific safety dossier. QT prolongation, serotonergic toxicity, constipation or masking of ileus, hypersensitivity and altered clearance in severe hepatic disease require patient and drug-list review; reproductive and paediatric veterinary safety is not established.
Clinical practicality 8.0/10
The 2 mg/ml solution permits accurate weight-based IV or IM dosing in hospital, but q6-12h treatment requires repeated staff administration and larger dogs may need more than one 4 ml ampoule. The exact human ampoule is not authorised for SC use.
Full-course cost-effectiveness -
Price was not assessed and is excluded from the overall score.
Important safety and use flags
Do not combine with apomorphine: profound hypotension and loss of consciousness have been reported. This is especially relevant when apomorphine is being considered as an emetic in a dog. Rule out gastrointestinal obstruction, progressive ileus and gastric distension when clinically plausible. Ondansetron is not prokinetic and suppression of vomiting must not delay diagnosis or decompression. Review congenital long-QT risk, bradyarrhythmia, heart failure, hypokalaemia or hypomagnesaemia and other QT-prolonging drugs; use ECG monitoring when the combined risk is clinically important. Review serotonergic medicines and monitor for agitation, tremor, hyperreflexia, hyperthermia, diarrhoea or autonomic instability; stop and reassess if serotonin toxicity is suspected. Severe hepatic disease may reduce clearance and increase exposure. Use the lowest effective regimen and reassess interval, adverse effects and concurrent hepatically cleared medicines. Do not use after hypersensitivity to ondansetron or another 5-HT3 antagonist; rare anaphylaxis and bronchospasm require immediate treatment. Correct dehydration and clinically important electrolyte or acid-base disturbance, investigate the underlying cause and track vomiting, nausea behaviour, intake and bowel function. Symptom control is not treatment of the disease. Give IV doses slowly and follow aseptic single-use ampoule practice. This exact human product is recorded for IV/IM administration; do not assume that veterinary SC pharmacokinetic data authorise SC use of this presentation. Assessment sources +
Close
Cat
Off-label IV or IM ondansetron for short-term control of clinically important nausea and active vomiting in cats
6.7/10
Situational / acceptable
Details →
8 mg/4 ml, 4 ml ampoule, solution for injection, human medicine
Assessed clinical scope Cat · Off-label IV or IM ondansetron for short-term control of clinically important nausea and active vomiting in cats · IV,IM
Care setting Clinic or hospital treatment after assessment of the cause, hydration, electrolytes and obstruction risk; repeated dosing and response are supervised by the veterinary team
vetman score
6.7/10
Situational / acceptable
Evidence confidence: Medium
Georgia: Yes, human · № რ-041727 · Verified on 16 Oct 2026
Off-label use
A clinically usable off-label feline antiemetic in a precisely doseable 2 mg/ml ampoule, but efficacy evidence is narrower and less certain than its frequent use suggests. Treat the underlying cause, distinguish active vomiting from reflux or obstruction, and monitor relevant cardiac, electrolyte and interaction risks.
Regulatory and scientific credibility 6.0/10
The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and its animal use remains off-label.
Clinical efficacy 6.5/10
Feline consensus and controlled peri-anaesthetic studies support ondansetron as an antiemetic, while a current systematic review judges the evidence limited, timing-dependent and lower-certainty than for maropitant. Direct trials across naturally occurring systemic and gastrointestinal disease remain sparse.
Safety and tolerability 6.5/10
Ondansetron is generally well tolerated at veterinary doses, but these exact human products have no dog- or cat-specific safety dossier. QT prolongation, serotonergic toxicity, constipation or masking of ileus, hypersensitivity and altered clearance in severe hepatic disease require patient and drug-list review; reproductive and paediatric veterinary safety is not established.
Clinical practicality 8.5/10
The 2 mg/ml solution permits accurate small-volume feline dosing by IV or IM routes and one 4 ml ampoule is ample for a typical cat. Repeated q6-12h treatment still requires clinical handling, asepsis and monitoring, and the exact human ampoule is not authorised for SC use.
Full-course cost-effectiveness -
Price was not assessed and is excluded from the overall score.
Important safety and use flags
Do not combine with apomorphine: profound hypotension and loss of consciousness have been reported. This is especially relevant when apomorphine is being considered as an emetic in a dog. Rule out gastrointestinal obstruction, progressive ileus and gastric distension when clinically plausible. Ondansetron is not prokinetic and suppression of vomiting must not delay diagnosis or decompression. Review congenital long-QT risk, bradyarrhythmia, heart failure, hypokalaemia or hypomagnesaemia and other QT-prolonging drugs; use ECG monitoring when the combined risk is clinically important. Review serotonergic medicines and monitor for agitation, tremor, hyperreflexia, hyperthermia, diarrhoea or autonomic instability; stop and reassess if serotonin toxicity is suspected. Severe hepatic disease may reduce clearance and increase exposure. Use the lowest effective regimen and reassess interval, adverse effects and concurrent hepatically cleared medicines. Do not use after hypersensitivity to ondansetron or another 5-HT3 antagonist; rare anaphylaxis and bronchospasm require immediate treatment. Correct dehydration and clinically important electrolyte or acid-base disturbance, investigate the underlying cause and track vomiting, nausea behaviour, intake and bowel function. Symptom control is not treatment of the disease. Give IV doses slowly and follow aseptic single-use ampoule practice. This exact human product is recorded for IV/IM administration; do not assume that veterinary SC pharmacokinetic data authorise SC use of this presentation. Assessment sources +
Close
Administration route
Intravenous, Intramuscular
Registration
Georgia
Yes, human
In force until 30 Jul 2029
Human (Ministry of Health, RAMA)
In the register: ონო 8 მგ/4 მლ, 4 მლ ამპულა, საინექციო ხსნარი
№ რ-041727
Verified on: 16 Oct 2026
EU
No
UK
No
US
No
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
